Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Ethos Spa Announces the Addition of Xeomin® Botox-Alternative Treatments to Its Line of Popular Anti-aging Treatments
  • USA - English


News provided by

Ethos Spa and Laser Skin Centers

May 28, 2014, 03:00 ET

Share this article

Share toX

Share this article

Share toX

Xeonine treatments at Ethos Spa offers an additive-free option to Botox for frown lines and deep wrinkles
Xeonine treatments at Ethos Spa offers an additive-free option to Botox for frown lines and deep wrinkles

Summit, New Jersey (PRWEB) May 28, 2014 -- Ethos Spa Skin and Laser Centers has announced the addition of Xeomin® to its growing line of anti-aging injectable products used that target deep lines and wrinkles. Xeomin is an additives-free Botox alternative for reducing or eliminating glabellar lines—those deep vertical frown lines on the face that resemble the number 11 between the eyebrows. Xeomin is often used along with Botox to treat wrinkles, severe frown lines and crow’s feet.

Xeonine is a “naked” (additive-free) form of the botulinum toxin type A.

Post this

Manufactured by Merz Aesthetics, Xeomin works by softening lines and wrinkles, and by blocking signals between facial nerves and muscles to prevent muscle contractions. Xeomin’s effects become visible within one week, and the results last from three to six months, making it comparable to Botox in terms of both onset and duration of results.

Xeomin gained U.S. approval after two pivotal clinical trials involving 16 investigational sites and 547 healthy adult patients whose glabellar lines were significantly reduced within 30 days of their first Xeomin injection. Because it is a “naked” (additive-free) form of the botulinum toxin type A, Xeomin is the only botulinum toxin currently approved in the U.S. that does not require refrigeration prior to reconstitution.

Anti-aging products like Botox, Dysport and Xeomin have plenty in common, but they also have some important differences. Although all three contain the botulinum toxin, Xeomin is the only pure form of botulinum toxin type A, which may lessen the patient's likelihood of developing antibodies and triggering an allergic reaction.

Originally prescribed to treat Cervical Dystonia (a painful condition in which neck muscles contract involuntarily) and Blepharospasm (an abnormal contractions or twitch of the eyelid,) Xeomin has being used in Europe for cosmetic procedures to reduce fine lines and wrinkles for years.

Many patients and practitioners prefer neurotoxins for anti-aging cosmetic treatments instead of microdermabrasion and chemical peels because the botulinum toxin works more directly and releases wrinkles for months at a time. Plus, injectable neurotoxin treatments do not require the same downtime or cost commitments as traditional facial surgeries such as face or brow lifts. Injectable products such as Xeomin, Botox and Dysport require only a brief office visit, and most patients return to work that same day.

Both Botox and Xeomin take about 7 days for the full effects to be visible, and results last an average three to six months before another treatment is required.

For more information on Xeomin anti-aging treatments or any of the expert aesthetic services available at the Ethos Spa, Skin and Laser Center, visit the Ethos Spa website, call the Summit location at (908) 273-5400, or call the Englewood location at (201) 541-6600.

About Hardik Soni, M.D. and Ethos Spa, Skin and Laser Center:

Ethos Spa, Skin and Laser Center Medical Director Hardik Soni, M.D. strives to achieve the best possible results for his patients by drawing on his experience and proficiency with multiple laser platforms, earned from having performed more than 15,000 cosmetic treatments including botulinum injection (Botox and Dysport), dermal fillers (Juvederm, Restylane, Radiesse), laser hair removal, chemical peels and laser skin rejuvenation. He is a platinum level injector with Allergan, the makers of Botox and Juvederm; his primary focus is on minimally invasive and non-invasive cosmetic procedures including Aesthera Candela, Cutera, Fraxel, Sciton and Syneron. Soni believes in a more conservative approach to cosmetic procedures, and prioritizes patient education. Clients are able to decide on their own ideal treatment after discussing their options, and weighing the expected outcomes, costs and risks.

He finished his undergraduate studies at Johns Hopkins University in Baltimore, Maryland and is board certified in Emergency Medicine. Soni currently works as an emergency room physician at Overlook Medical Center in Summit, New Jersey, as well as serving as medical director of Ethos Spa, Skin and Laser Center. He was recently chosen to the Advisory Medical Panel of Bella Magazine in NYC.

Ethos Spa, Skin and Laser Center is committed to providing the safest, most effective aesthetic procedures, customized to each individual client, utilizing the latest advances in non-invasive cosmetic treatments and technologies. Within a peaceful, luxurious environment, patients can choose from a wide array of cosmetic services and products to enhance the skin’s appearance.

###

Hardik Soni, Ethos Spa and Laser Skin Centers, http://www.ethosspa.com, +1 908-273-5400, [email protected]

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.